# Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers

> **NCT06607770** · PHASE1,PHASE2 · RECRUITING · sponsor: **Zhou Chengzhi** · enrollment: 20 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Karelizumab+Apatinib

## Key facts

- **NCT ID:** NCT06607770
- **Lead sponsor:** Zhou Chengzhi
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2026-08
- **Final completion:** 2027-08
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06607770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06607770, "Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06607770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*